Literature DB >> 1975262

Induction of murine lymphokine-activated killer cells by recombinant IL-7.

D H Lynch1, R E Miller.   

Abstract

The data demonstrate that IL-7, a cytokine that was originally identified, purified, and cloned based upon its ability to support the growth of pre-B cells in vitro, also induces proliferation and promotes the generation of lymphokine-activated killer (LAK) cell activity in populations of resting peripheral lymphoid cells. Although the kinetics of LAK induction by IL-7 (which peaked at days 6 to 8 of culture) was slower than that detected in cultures containing IL-2 (which peaked at day 4), IL-7 was significantly more effective at maintaining cytotoxic activity over longer periods of time, and greater viable cell recoveries, than was IL-2. A wide range of murine tumor target cells were found to be lysed in an MHC-unrestricted fashion by IL-7 induced LAK, but syngeneic Con A-induced lymphoblasts were not; nor were target cells from the human tumors K562 or Daudi lysed by IL-7 LAK. IL-7 LAK were induced in populations of lymphoid cells obtained from secondary lymphoid tissues (peripheral lymph nodes and spleen), but not from primary lymphoid tissues (thymus and bone marrow). LAK induced by IL-7 from unfractionated populations of lymphoid cells were completely eliminated by treatment with anti-CD8 or anti-Thy-1+C, and unaffected by treatment with anti-CD4, anti-asialo GM1 or anti-NK1.1+C. Interestingly, although no detectable CD4+ effector cells could be detected in populations of LAK generated from unfractionated populations of lymphoid cells stimulated by IL-7, they were found to be generated from populations of lymphoid cells from which CD8+ cells had been eliminated before being cultured in medium containing IL-7. These data suggest that CD4+ T cells do not normally give rise to IL-7-induced LAK unless they are first separated from CD8+ T cells. LAK induced by IL-7 appear to be distinct from LAK activity induced by IL-2 in that there is no detectable involvement of NK-like effector cells at either the precursor or effector cell stages.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1975262

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo.

Authors:  T Aoki; K Tashiro; S Miyatake; T Kinashi; T Nakano; Y Oda; H Kikuchi; T Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

2.  Regulatory effects of interleukin-7 on renal tumor infiltrating lymphocytes.

Authors:  P Ditonno; C L Tso; T Sakata; J B deKernion; A Belldegrun
Journal:  Urol Res       Date:  1992

3.  Interleukin 7 induces CD4+ T cell-dependent tumor rejection.

Authors:  H Hock; M Dorsch; T Diamantstein; T Blankenstein
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

4.  Interleukin 7 induces cytokine secretion and tumoricidal activity by human peripheral blood monocytes.

Authors:  M R Alderson; T W Tough; S F Ziegler; K H Grabstein
Journal:  J Exp Med       Date:  1991-04-01       Impact factor: 14.307

5.  Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma.

Authors:  I G Schmidt-Wolf; S Finke; B Trojaneck; A Denkena; P Lefterova; N Schwella; H G Heuft; G Prange; M Korte; M Takeya; T Dorbic; A Neubauer; B Wittig; D Huhn
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

6.  Interleukin 7 promotes long-term in vitro growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo.

Authors:  D H Lynch; R E Miller
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

7.  Augmentation by tumor necrosis factor alpha of the systemic therapeutic effect of lymphokine-activated killer cells in adoptive immunotherapy of murine tumor.

Authors:  K Kato; T Tanabe; T Agatsuma; S Suzuki; H Nitanai; Y Hashimoto
Journal:  Jpn J Cancer Res       Date:  1991-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.